Interferon News and Research

RSS

TLR7 and MARK1 genomic variants impact COVID-19 prognosis

Researchers conduct a massive exome-wide genome study to explore the connections between gene variants/deleterious mutations and COVID-19 outcomes.

3 Apr 2022

An in-depth analysis of pathogenesis of SARS-CoV-2 and therapeutic options for COVID-19

Scientists discuss the pathogenic characteristics of SARS-CoV-2 and available therapeutic interventions for treating COVID-19.

3 Apr 2022

Study explores molecular mechanisms underlying SARS-CoV-2 infection of macrophages and the induction of pro-inflammatory cytokines

Researchers examined the role of sialic acid-binding immunoglobulin-type lectins-1, a myeloid cell-specific receptor, in facilitating SARS-CoV-2 infection of ACE2-deficient macrophages and its effect on pro-inflammatory cytokine expression.

1 Apr 2022

Study determines the molecular signatures of monocytes and regulatory T cells in the circulating blood of COVID-19 patients

Researchers examined the unique clusters of monocytes and regulatory T cells in the circulating blood from convalescent COVID-19 patients over a prolonged period after recovery, using scRNA sequencing.

31 Mar 2022

Role of SARS-CoV-2 S1 subunit in severe COVID-19

A new study aimed to determine whether portions of the SARS-CoV-2 spike protein are capable of activating innate immune cells like Gal-3.

30 Mar 2022

Antiviral functions of interferon regulatory factors during human coronavirus infection

Researchers assessed the roles of the interferon regulatory factors: IRF1, IRF3, and IRF7 in infections by human coronaviruses.

30 Mar 2022

Preclinical investigation of intranasal adjuvanted COVID-19 vaccine

A new study reported systemic and mucosal immunity against SARS-CoV-2 via intranasal delivery of a vaccine containing recombinant SARS-CoV-2 antigens, nucleocapsid, and spike subunit.

30 Mar 2022

SARS-CoV-2 nucleocapsid protein linked to COVID-19 severity

The emergence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes respiratory coronavirus disease 2019 (COVID-19) triggered an unprecedented public health emergency. Human mobility patterns were fundamental to the spread of SARS-CoV-2 globally. The situation is particularly acute in a country like Saudi Arabia, which has seen more than 750,000 cases and over 9,000 deaths as of March 30th, 2022.

29 Mar 2022

The different actions of CBD in SARS-CoV-2 infection

An article has described the role of cannabidiol as a potential inhibitor of hyperinflammation in SARS-CoV-2 infection.

29 Mar 2022

Viewpoint explains how T cell testing can help research on population-level SARS-CoV-2 adaptive immunity and inform public health policies

A recent viewpoint illustrated that evaluating T cell responses to COVID-19 is essential to inform public health initiatives.

29 Mar 2022

Results of Phase 3 Nanocovax SARS-CoV-2 vaccine trial suggest robust effectiveness

A new study presented the findings of the Phase 3 trial of the Nanocovax coronavirus disease 2019 (COVID-19) vaccine.

29 Mar 2022

Examining differences in neurological manifestations induced by SARS-CoV-2 variants in hamsters

Researchers evaluated the neurological complications due to SARS-CoV-2 D614G strain, and variants of concern, Delta and Omicron in a hamster model.

28 Mar 2022

Study investigates room-temperature stable, self-amplifying RNA vaccine against SARS-CoV-2

Researchers applied a previously developed thermostable self-amplifying ribonucleic acid vaccine to COVID-19.

28 Mar 2022

Durability and functionality of the humoral and T-cell response to SARS-CoV-2 and its variants in recovered patients

A recent study investigated the potency and functionality of T-cell and humoral responses against the SARS-CoV-2 wild-type strain and its variants.

28 Mar 2022

Tuberculosis infection protects mice against COVID-19

To study if prior Mtb infection affects the response to CoV2 infection, K18-hACE2 (ACE2) and C57BL/6 (B6) mice were infected with Mtb, and post thirty days, were exposed to CoV2.

27 Mar 2022

Study evaluates the prevalence of autoantibodies targeting type I interferons in critically-ill COVID-19 patients

Researchers assessed the prevalence of antibodies that neutralize the type I interferon antiviral activity and reactivate herpesviruses such as herpes simplex virus types 1 and 2 and/or cytomegalovirus infections in patients with critical COVID-19.

24 Mar 2022

T-cell and neutralizing antibody response after a third COVID-19 vaccine dose in hemodialysis patients

Researchers compare the impact of a third mRNA COVID-19 vaccine in hemodialysis patients by measuring antibody levels and IFN-γ responses.

23 Mar 2022

Monoclonal antibodies found to prevent lung inflammation in SARS-CoV-2-Omicron-infected mice

Researchers investigated how monoclonal antibodies, S309 and AZD7442, reduced lung infection in mice infected with the SARS-CoV-2 new variant of concern Omicron's BA.1, BA.1.1, and BA.2 sublineages.

23 Mar 2022

Sex-specific differences in T-cell responses to COVID-19

Researchers evaluate both neutralizing activity and T-cell responses in SARS-CoV-2 infected individuals with mild symptoms linked to a single spreading event.

20 Mar 2022

How does the non-structural protein 1 affect COVID-19 pathogenicity?

Researchers discuss the effects of the SARS-CoV-2 non-structural protein 1 (Nsp1), which binds to the ribosomal subunit thus inhibiting translation.

20 Mar 2022

Interferon News and Research

TLR7 and MARK1 genomic variants impact COVID-19 prognosis

An in-depth analysis of pathogenesis of SARS-CoV-2 and therapeutic options for COVID-19

Study explores molecular mechanisms underlying SARS-CoV-2 infection of macrophages and the induction of pro-inflammatory cytokines

Study determines the molecular signatures of monocytes and regulatory T cells in the circulating blood of COVID-19 patients

Role of SARS-CoV-2 S1 subunit in severe COVID-19

Antiviral functions of interferon regulatory factors during human coronavirus infection

Preclinical investigation of intranasal adjuvanted COVID-19 vaccine

SARS-CoV-2 nucleocapsid protein linked to COVID-19 severity

The different actions of CBD in SARS-CoV-2 infection

Viewpoint explains how T cell testing can help research on population-level SARS-CoV-2 adaptive immunity and inform public health policies

Results of Phase 3 Nanocovax SARS-CoV-2 vaccine trial suggest robust effectiveness

Examining differences in neurological manifestations induced by SARS-CoV-2 variants in hamsters

Study investigates room-temperature stable, self-amplifying RNA vaccine against SARS-CoV-2

Durability and functionality of the humoral and T-cell response to SARS-CoV-2 and its variants in recovered patients

Tuberculosis infection protects mice against COVID-19

Study evaluates the prevalence of autoantibodies targeting type I interferons in critically-ill COVID-19 patients

T-cell and neutralizing antibody response after a third COVID-19 vaccine dose in hemodialysis patients

Monoclonal antibodies found to prevent lung inflammation in SARS-CoV-2-Omicron-infected mice

Sex-specific differences in T-cell responses to COVID-19

How does the non-structural protein 1 affect COVID-19 pathogenicity?

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Latest News